Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 6/2017

23.08.2017 | Clinical Investigation

Retinal sensitivity after displacement of submacular hemorrhage due to polypoidal choroidal vasculopathy: effectiveness and safety of subretinal tissue plasminogen activator

verfasst von: Shuhei Kimura, Yuki Morizane, Ryo Matoba, Mio Hosokawa, Yusuke Shiode, Masayuki Hirano, Shinichiro Doi, Shinji Toshima, Kosuke Takahashi, Mika Hosogi, Atsushi Fujiwara, Fumio Shiraga

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the effectiveness of displacement of submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV) by assessing retinal sensitivity using microperimetry.

Methods

We retrospectively reviewed the medical records of 11 consecutive PCV patients with SMH. All patients underwent vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-air exchange, followed by antivascular endothelial growth factor therapy using a pro re nata regimen. The retinal sensitivity was measured by use of microperimetry before and after surgery.

Results

The mean (SD) age of the patients was 74.1 ± 9.4 years. The mean SMH diameter was 6.8 ± 5.2 disc diameters. The best-corrected visual acuity (BCVA), mean retinal sensitivity, and mean number of measure points with a sensitivity ≥10 dB before the surgery were 0.94 ± 0.49, 4.2 ± 4.5 dB, and 15.6 ± 15.1 points, respectively. These had significantly improved 6 months after surgery (0.39 ± 0.37, 15.6 ± 7.3 dB, and 50.9 ± 22.2 points, respectively; P < 0.05 for all outcome measures). The mean number of measure points with an absolute scotoma before surgery had decreased significantly 6 months after surgery (from 40.5 ± 15.0 to 9.4 ± 16.0 points; P < 0.001).

Conclusions

Displacement of SMH effectively improves retinal sensitivity as well as BCVA.
Literatur
1.
Zurück zum Zitat Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639–48.CrossRefPubMed Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639–48.CrossRefPubMed
2.
Zurück zum Zitat Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392–6.CrossRefPubMed Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392–6.CrossRefPubMed
3.
Zurück zum Zitat Cho JH, Ryoo N-K, Cho KH, Park SJ, Park KH, Woo SJ. Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;169:79–88.CrossRefPubMed Cho JH, Ryoo N-K, Cho KH, Park SJ, Park KH, Woo SJ. Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;169:79–88.CrossRefPubMed
4.
Zurück zum Zitat Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116:1326–32.CrossRefPubMed Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116:1326–32.CrossRefPubMed
5.
Zurück zum Zitat Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237:273–7.CrossRefPubMed Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237:273–7.CrossRefPubMed
6.
Zurück zum Zitat Haupert CL, McCuen BW, Jaffe GJ, Steuer ER, Cox TA, Toth CA, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131:208–15.CrossRefPubMed Haupert CL, McCuen BW, Jaffe GJ, Steuer ER, Cox TA, Toth CA, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131:208–15.CrossRefPubMed
7.
Zurück zum Zitat Fine HF, Iranmanesh R, Del Priore LV, Barile GR, Chang LK, Chang S, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina. 2010;30:1588–94.CrossRefPubMed Fine HF, Iranmanesh R, Del Priore LV, Barile GR, Chang LK, Chang S, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina. 2010;30:1588–94.CrossRefPubMed
8.
Zurück zum Zitat Kimura S, Morizane Y, Hosokawa M, Shiode Y, Kawata T, Doi S, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol. 2015;159:683–9.CrossRefPubMed Kimura S, Morizane Y, Hosokawa M, Shiode Y, Kawata T, Doi S, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol. 2015;159:683–9.CrossRefPubMed
9.
Zurück zum Zitat van Zeeburg EJT, van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica. 2013;229:1–14.CrossRefPubMed van Zeeburg EJT, van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica. 2013;229:1–14.CrossRefPubMed
10.
Zurück zum Zitat Steel DHW, Sandhu SS. Submacular haemorrhages associated with neovascular age-related macular degeneration. Br J Ophthalmol. 2011;95:1051–7.CrossRefPubMed Steel DHW, Sandhu SS. Submacular haemorrhages associated with neovascular age-related macular degeneration. Br J Ophthalmol. 2011;95:1051–7.CrossRefPubMed
11.
Zurück zum Zitat Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723–9.CrossRefPubMed Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723–9.CrossRefPubMed
12.
Zurück zum Zitat Benner JD, Morse LS, Toth CA, Landers MB, Hjelmeland LM. Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Arch Ophthalmol. 1991;109:1731–6.CrossRefPubMed Benner JD, Morse LS, Toth CA, Landers MB, Hjelmeland LM. Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Arch Ophthalmol. 1991;109:1731–6.CrossRefPubMed
13.
Zurück zum Zitat Hillenkamp J, Surguch V, Framme C, Gabel V-P, Sachs HG. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010;248:5–11.CrossRefPubMed Hillenkamp J, Surguch V, Framme C, Gabel V-P, Sachs HG. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010;248:5–11.CrossRefPubMed
14.
Zurück zum Zitat Vujosevic S, Midena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci. 2006;47:3044–51.CrossRefPubMed Vujosevic S, Midena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci. 2006;47:3044–51.CrossRefPubMed
15.
Zurück zum Zitat Pranger F, Michels S, Geitzenauer W, Schmidt-Erfurth U, Simader C. Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (Avastin) therapy. Retina. 2008;28:682–8.CrossRef Pranger F, Michels S, Geitzenauer W, Schmidt-Erfurth U, Simader C. Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (Avastin) therapy. Retina. 2008;28:682–8.CrossRef
16.
Zurück zum Zitat Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab. Retina. 2010;30:1017–24.CrossRefPubMed Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab. Retina. 2010;30:1017–24.CrossRefPubMed
17.
Zurück zum Zitat Ozdemir H, Karacorlu M, Senturk F, Karacorlu SA, Uysal O. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration. Acta Ophthalmol. 2010;90:71–5.CrossRefPubMed Ozdemir H, Karacorlu M, Senturk F, Karacorlu SA, Uysal O. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration. Acta Ophthalmol. 2010;90:71–5.CrossRefPubMed
18.
Zurück zum Zitat Crossland M, Jackson M-L, Seiple WH. Microperimetry: a review of fundus related perimetry. Optom Rep. 2012;2:11–5. Crossland M, Jackson M-L, Seiple WH. Microperimetry: a review of fundus related perimetry. Optom Rep. 2012;2:11–5.
19.
Zurück zum Zitat Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155:118–26.CrossRefPubMed Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155:118–26.CrossRefPubMed
20.
Zurück zum Zitat Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55:501–15.CrossRefPubMed Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55:501–15.CrossRefPubMed
21.
Zurück zum Zitat Treatment of Age-Related Macular Degeneration With Photodynamic Therapy. (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Arch Ophthalmol. 1999;117:1329–45.CrossRef Treatment of Age-Related Macular Degeneration With Photodynamic Therapy. (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Arch Ophthalmol. 1999;117:1329–45.CrossRef
22.
Zurück zum Zitat Sato S, Hirooka K, Baba T, Tenkumo K, Nitta E, Shiraga F. Correlation between the ganglion cell inner plexiform layer thickness measured with Cirrus HD-OCT and macular visual field sensitivity measured with microperimetry. Invest Ophthalmol Vis Sci. 2012;54:3046–51.CrossRef Sato S, Hirooka K, Baba T, Tenkumo K, Nitta E, Shiraga F. Correlation between the ganglion cell inner plexiform layer thickness measured with Cirrus HD-OCT and macular visual field sensitivity measured with microperimetry. Invest Ophthalmol Vis Sci. 2012;54:3046–51.CrossRef
23.
Zurück zum Zitat Wu Z, Jung CJ, Ayton LN, Luu CD, Guymer RH. Test–retest repeatability of microperimetry at the border of deep scotomas. Invest Ophthalmol Vis Sci. 2015;56:2606–11.CrossRefPubMed Wu Z, Jung CJ, Ayton LN, Luu CD, Guymer RH. Test–retest repeatability of microperimetry at the border of deep scotomas. Invest Ophthalmol Vis Sci. 2015;56:2606–11.CrossRefPubMed
24.
Zurück zum Zitat Koh A, Lee WK, Chen L-J, Chen S-J, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.CrossRefPubMed Koh A, Lee WK, Chen L-J, Chen S-J, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.CrossRefPubMed
25.
Zurück zum Zitat Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97–102.CrossRefPubMed Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97–102.CrossRefPubMed
26.
Zurück zum Zitat Okanouchi T, Toshima S, Kimura S, Morizane Y, Shiraga F. Novel technique for subretinal injection using local removal of the internal limiting membrane. Retina. 2016;36:1035–8.CrossRefPubMed Okanouchi T, Toshima S, Kimura S, Morizane Y, Shiraga F. Novel technique for subretinal injection using local removal of the internal limiting membrane. Retina. 2016;36:1035–8.CrossRefPubMed
27.
Zurück zum Zitat Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96:708–13.CrossRefPubMed Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96:708–13.CrossRefPubMed
28.
Zurück zum Zitat Kim JH, Kim JW, Lee TG, Lew YJ. Treatment outcomes in eyes with polypoidal choroidal vasculopathy with poor baseline visual acuity. J Ocul Pharmacol Ther. 2015;31:241–7.CrossRefPubMed Kim JH, Kim JW, Lee TG, Lew YJ. Treatment outcomes in eyes with polypoidal choroidal vasculopathy with poor baseline visual acuity. J Ocul Pharmacol Ther. 2015;31:241–7.CrossRefPubMed
29.
Zurück zum Zitat Chang YS, Kim JH, Kim JW, Lee TG, Kim CG, Cho SW. Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome. Graefes Arch Clin Exp Ophthalmol. 2016;254:1–7.CrossRef Chang YS, Kim JH, Kim JW, Lee TG, Kim CG, Cho SW. Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome. Graefes Arch Clin Exp Ophthalmol. 2016;254:1–7.CrossRef
30.
Zurück zum Zitat Lin T-C, Hwang D-K, Lee F-L, Chen S-J. Visual prognosis of massive submacular hemorrhage in polypoidal choroidal vasculopathy with or without combination treatment. J Chin Med Assoc. 2016;79:159–65.CrossRefPubMed Lin T-C, Hwang D-K, Lee F-L, Chen S-J. Visual prognosis of massive submacular hemorrhage in polypoidal choroidal vasculopathy with or without combination treatment. J Chin Med Assoc. 2016;79:159–65.CrossRefPubMed
31.
Zurück zum Zitat Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135–8.CrossRefPubMed Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135–8.CrossRefPubMed
32.
Zurück zum Zitat Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53:5877–80.CrossRefPubMed Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53:5877–80.CrossRefPubMed
33.
Zurück zum Zitat Christoforidis JB, Williams MM, Wang J, Jiang A, Pratt C, Abdel-Rasoul M, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina. 2013;33:946–52.CrossRefPubMedPubMedCentral Christoforidis JB, Williams MM, Wang J, Jiang A, Pratt C, Abdel-Rasoul M, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina. 2013;33:946–52.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2011;249:1153–7.CrossRefPubMed Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2011;249:1153–7.CrossRefPubMed
35.
Zurück zum Zitat Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Retinal pigment epithelium tear after intravitreal aflibercept injection. Clin Ophthalmol. 2013;7:1287–9.CrossRefPubMedPubMedCentral Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Retinal pigment epithelium tear after intravitreal aflibercept injection. Clin Ophthalmol. 2013;7:1287–9.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Ersoz MG, Karacorlu M, Arf S, Sayman Muslubas I, Hocaoglu M. Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management. Surv Ophthalmol. 2017;62:493–505.CrossRefPubMed Ersoz MG, Karacorlu M, Arf S, Sayman Muslubas I, Hocaoglu M. Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management. Surv Ophthalmol. 2017;62:493–505.CrossRefPubMed
Metadaten
Titel
Retinal sensitivity after displacement of submacular hemorrhage due to polypoidal choroidal vasculopathy: effectiveness and safety of subretinal tissue plasminogen activator
verfasst von
Shuhei Kimura
Yuki Morizane
Ryo Matoba
Mio Hosokawa
Yusuke Shiode
Masayuki Hirano
Shinichiro Doi
Shinji Toshima
Kosuke Takahashi
Mika Hosogi
Atsushi Fujiwara
Fumio Shiraga
Publikationsdatum
23.08.2017
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 6/2017
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-017-0530-0

Weitere Artikel der Ausgabe 6/2017

Japanese Journal of Ophthalmology 6/2017 Zur Ausgabe

Scientific Reviewers

Scientific Reviewers

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.